Start of the Phase 2 Clinical Study of the Vaxine-originated COVID-19 vaccine in Iran

On May 30th, CinnaGen company announced the start of Phase 2 human clinical trial of its potential COVID-19 vaccine. This vaccine candidate was originally developed by Vaxine Pty Ltd under the brand name COVAX-19 and is a collaboration between CinnaGen and Vaxine. As of June 1st, all the 400 planned volunteers were enrolled in the study and were injected with the first dose of either the COVID-19 vaccine candidate or the saline placebo in a 3:1 ratio. The second dose will be administered with an interval of 21 days and all participants will be followed up for 6 months after the injections. The Iranian Food and Drug Administration (IFDA) approved the initiation of this Phase 2 clinical study based on preclinical and clinical data on COVAX-19. After this step, CinnaGen will advance into a Phase 3 efficacy and safety study on a larger population.